HALO

HALOZYME THERAPEUTICS INC

HALO·40637H109·US·Common Stock·Healthcare - Biotechnology-13D/G

HALO (HALOZYME THERAPEUTICS INC) is held by 233 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($1B), VANGUARD CAPITAL MANAGEMENT LLC ($418.8M), VANGUARD PORTFOLIO MANAGEMENT LLC ($414.8M). Net institutional sentiment: Mixed. In Q2 2026, 1 member of Congress and 121 funds bought HALO.

233
Holders
(19 Elite)
$8B
Total Value
52% (233)
Consensus
121 buying - 112 selling
13F: Insider & Congress: Updated regularly
HALO

Smart Money Verdict

View all
Loading verdict
Held by 233 funds
19 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Aug 19, 2026 · Activists Apr 30, 2026 · Congress Apr 7, 2026

InsiderTHTorley HelenSell $1.0MAug 19, 2026
InsiderTHTorley HelenSell $766KAug 19, 2026
InsiderTHTorley HelenSell $345KAug 19, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
13.3M(+0.1%)$1B0.0%+116.68%
32
Increased
5.4M(+1.5%)$418.8M0.0%+51.51%
32
Increased
5.3M(+0.9%)$414.8M0.0%+51.62%
31
Increased
5.2M(+4.9%)$405.4M0.0%+148.46%
33
Decreased
3.2M(-20.8%)$248.7M0.0%+90.51%
0
Increased
2.8M(+10.6%)$221.7M0.0%+72.37%
34
Increased
2.8M(+3.4%)$216.8M0.2%+61.82%
38
Decreased
2.7M(-5.9%)$214.5M0.0%+93.54%
0
Increased
2.5M(+0.6%)$197.3M0.0%+271.83%
31
Decreased
2.5M(-0.6%)$196.5M0.6%+54.56%
0
Increased
2.1M(+0.5%)$163.5M0.0%+150.90%
30
Increased
2M(+7.4%)$157M0.1%+60.85%
33
Increased
1.9M(+180.9%)$151.7M0.6%+52.03%
69
Increased
1.8M(+12.4%)$141.7M0.3%+67.28%
41
Decreased
1.7M(-11.1%)$133.4M0.1%+84.42%
0
Increased
1.7M(+4.3%)$129.4M0.1%+52.41%
32
Increased
1.5M(+63.3%)$116.8M0.0%+55.00%
44
Increased
1.5M(+1.8%)$116.7M0.3%+77.85%
37
Decreased
1.4M(-4.4%)$110.9M0.1%+94.46%
0
Decreased
1.7M(-2.3%)$109.6M0.0%+171.46%
0

Showing 1-20 of 252

1 / 13
HALOHALOHALOZYME THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used